Acessibilidade / Reportar erro

Recurrent cutaneous leishmaniasis* * Study conducted at Brasilia University Hospital (HUB-UnB) - Brasilia (DF), Brazil.

Leishmaniose recidiva cútis

Abstracts

We present a case of an 18-year-old male patient who, after two years of inappropriate treatment for cutaneous leishmaniasis, began to show nodules arising at the edges of the former healing scar. He was immune competent and denied any trauma. The diagnosis of recurrent cutaneous leishmaniasis was made following positive culture of aspirate samples. The patient was treated with N-methylglucamine associated with pentoxifylline for 30 days. Similar cases require special attention mainly because of the challenges imposed by treatment.

Leishmaniasis; Leishmaniasis, mucocutaneous; Pentoxifylline; Recurrence; Therapeutics


Paciente do sexo masculino, 18 anos. Dois anos após tratamento insuficiente para leishmaniose tegumentar americana, apresentou, na mesma localização, lesão formada por cicatriz atrófica central e nódulos verrucosos na periferia. Era imunocompetente, hígido e negava qualquer trauma local. O diagnóstico de leishmaniose recidiva cutis foi feito através de cultura do aspirado da lesão. Realizou tratamento com N-metilglucamina (20mgSbV/kg/dia) associado à pentoxifilina (1200mg/dia) durante 30 dias alcançando cura clínica. Os casos semelhantes requerem atenção diferenciada pela dificuldade ao tratamento.

Leishmaniose; Leishmaniose mucocutânea; Pentoxifilina; Recidiva; Terapêutica


Report

We present a case of an 18-year-old male patient from the northeast of Brazil. He had experienced an ulcer on the anterior face of his left thigh which was treated as American Cutaneous Leishmaniasis (ACL). The use of N-methylglucamine (7mgSbV/Kg/day) for 20 days ensured complete healing. However verrucous nodules began to appear at the periphery of the former atrophic scar two years after clinical cure (Figures 1 and 2). The patient presented no immunodeficiency.

FIGURE 1
Lesion with atrophic center permeated with hyperchromic areas and verrucous nodules on the borders
FIGURE 2
Detail of lesion formed by a central atrophic scar and verrucous nodules on the edges

A positive (6x5mm) Montenegro intradermoreaction was found, in addition to high titer (1:160) of anti-ACL antibodies showed by indirect immunofluorescence. The smear was negative, together with the cultures for mycobacteria and fungus. Histological examination showed pseudoepitheliomatous hyperplasia and linfohistioplasmocitoid granulomas (Figure 3).

FIGURE 3
Hematoxiciline and eosine stain - 40x: Histopathological examination with marked pseudoepitheliomatous hiperlasia and extensive dermal inflammatory infiltrate

The diagnosis of Recurrent Cutaneous Leishmaniasis (RCL) was confirmed after the positive culture of aspirate specimens using the McNeal, Novy & Nicolle culture medium.11. Calvopina M, Uezato H, Gomez EA, Korenaga M, Nonaka S, Hashiguchi Y. Leishmaniasis recidiva cutis due to Leishmania (Viannia) panamensis in subtropical Ecuador: isoenzymatic characterization. Int J Dermatol. 2006;45:116-20. The species L. (V.) braziliensis 22. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Manual de Vigilância da Leishmaniose Tegumentar Americana. 2. ed. atual. Brasília: Ministério da Saúde; 2007. 180 p. is endemic to the area of Brazil where the patient originated.

We decided to associate N-methylglucamine (20mgSbV/kg/day) with pentoxifylline (1200mg/day) for 30 days. 33. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2009:CD004834. , 44. Serafinella P, Cannavò SP, Vaccaro M, Guarneri F. Leishmaniasis recidiva cutis. Int J Dermatol. 2000;39:205-6. The patient achieved a long-term clinical cure, observed over a 3-year follow-up period.

RCL is rare, usually occurring within two years following the appearance of initial lesions. It is considered by many authors to be the result of inappropriate treatment.55. Ul Bari A, Raza N. Lupoid cutaneous leishmaniasis: a report of 16 cases. Indian J Dermatol Venereol Leprol. 2010;76:85. , 66. Costa JML, Lago EL, Magalhães AV, Marsden PD. Leishmaniasis recidiva a cutis caused by Leishmania Viannia braziliensis. An Bras Dermatol. 1996;71:329-33. Given the challenge of RCL we need to consider long-term follow-up of all cases which apparently have been wrongly treated.33. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2009:CD004834. , 44. Serafinella P, Cannavò SP, Vaccaro M, Guarneri F. Leishmaniasis recidiva cutis. Int J Dermatol. 2000;39:205-6. , 77. Momeni A-Z, Aminjavaheri M. Treatment of recurrent cutaneous leishmaniasis. Int J Dermatol. 1995;34:129-33. Using an association of pentoxifylline in the treatment regime was effective probably due to its immunomodulatory function and its ability to regulate tumor necrosis factor-α levels.88. Almeida OL, Santos JB. Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review. An Bras Dermatol. 2011;86:497-506.

9. Machado PR, Lessa H, Lessa M, Guimaraes LH, Bang H, Ho JL, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis. 2007;44:788-93.
- 1010. Gomes CM, Morais OO, Leite AS, Soares KA, Motta J de O, Sampaio RN. Periungual leishmaniasis. An Bras Dermatol. 2012;87:148-9.

REFERENCES

  • 1
    Calvopina M, Uezato H, Gomez EA, Korenaga M, Nonaka S, Hashiguchi Y. Leishmaniasis recidiva cutis due to Leishmania (Viannia) panamensis in subtropical Ecuador: isoenzymatic characterization. Int J Dermatol. 2006;45:116-20.
  • 2
    Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Manual de Vigilância da Leishmaniose Tegumentar Americana. 2. ed. atual. Brasília: Ministério da Saúde; 2007. 180 p.
  • 3
    González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2009:CD004834.
  • 4
    Serafinella P, Cannavò SP, Vaccaro M, Guarneri F. Leishmaniasis recidiva cutis. Int J Dermatol. 2000;39:205-6.
  • 5
    Ul Bari A, Raza N. Lupoid cutaneous leishmaniasis: a report of 16 cases. Indian J Dermatol Venereol Leprol. 2010;76:85.
  • 6
    Costa JML, Lago EL, Magalhães AV, Marsden PD. Leishmaniasis recidiva a cutis caused by Leishmania Viannia braziliensis. An Bras Dermatol. 1996;71:329-33.
  • 7
    Momeni A-Z, Aminjavaheri M. Treatment of recurrent cutaneous leishmaniasis. Int J Dermatol. 1995;34:129-33.
  • 8
    Almeida OL, Santos JB. Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review. An Bras Dermatol. 2011;86:497-506.
  • 9
    Machado PR, Lessa H, Lessa M, Guimaraes LH, Bang H, Ho JL, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis. 2007;44:788-93.
  • 10
    Gomes CM, Morais OO, Leite AS, Soares KA, Motta J de O, Sampaio RN. Periungual leishmaniasis. An Bras Dermatol. 2012;87:148-9.
  • *
    Study conducted at Brasilia University Hospital (HUB-UnB) - Brasilia (DF), Brazil.

Publication Dates

  • Publication in this collection
    June 2013

History

  • Received
    25 May 2012
  • Accepted
    16 Oct 2012
Sociedade Brasileira de Dermatologia Av. Rio Branco, 39 18. and., 20090-003 Rio de Janeiro RJ, Tel./Fax: +55 21 2253-6747 - Rio de Janeiro - RJ - Brazil
E-mail: revista@sbd.org.br